Predictors of Success of Different Treatment Modalities for Management of Ectopic Pregnancy

Table 2

Comparison of patient characteristics between single-dose and multiple-dose treatments with Mtx.

	Single-dose Mtx^1 ()	Multiple-dose Mtx^1 ()
Age (years)	31.02 ± 0.78	29.73 ± 0.72	0.227
Gravidity	2.67 ± 0.24	2.80 ± 0.19	0.685
Parity	0.94 ± 0.11	1.13 ± 0.19	0.401
βhCG^2 (day 0) (mIU/mL)	2978.64 ± 597.59	6610.56 ± 1431.62	0.024
βhCG^2 (1st day) (mIU/mL)	2533.28 ± 425.95	6336.46 ± 1333.94	0.010
βhCG^2 (4th day) (mlU/mL)	2344.11 ± 459.71	6575.70 ± 1557.45	0.013
βhCG^2 (7th day) (mIU/mL)	2255.87 ± 486.61	5615.10 ± 1485.46	0.039
Diameter of EP^3 mass (mm)	15.77 ± 2.18	32.96 ± 3.21	<0.01
Endometrial thickness (mm)	6.77 ± 0.47	6.62 ± 0.76	0.871
Overall success rate (%)	47/67 (70.14%)	21/30 (70%)	0.988

Mtx: methotrexate, ²βhCG: beta human chorionic gonadotropin, ³EP: ectopic pregnancy, statistical significance .